Skin cancer vaccine on the horizon

British researchers have begun testing a new vaccine that could potentially end up reversing the deadly skin cancer melanoma, according to a recent report by

Lindy Durrants, ha leads the research team at the University of Nottingham in England in the development of the vaccine, which contains DNA along with other biological materials from a patient’s tumor.

Durrants told that the goal of the vaccine is to “switch on” the patients’ own immunity systems to target the melanoma cells while leaving the healthy cells alone, according to the report.

“It is still at a very early stage and impossible to predict the outcome of the clinical trial but if our results from the lab are replicated in patients I think we have a good chance of dramatically improving the chances of successful treatment,” Durrants told “We are hoping that the vaccine will cure between 10 percent and 20 percent of patients with malignant melanoma.”

Durrants and her colleagues will begin immunizing test subjects in Nottingham City, Manchester and Newcastle in the very near future, according to the report. Researchers will begin with patients who have melanoma that has spread to other parts of the body.